Myocardial perfusion imaging method
View Patent ↗The present invention provides a method for using the partial adenosine A 2A receptor agonists having the following structure in myocardiological perfusion imaging.
1. A method of myocardial perfusion imaging of a mammal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A 2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A 2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the dose is from 0.0002 to 0.009 mg/kg.
2. The method of claim 1 , wherein the dose of CVT-3033 or CVT-3146 is from 0.10 to 5.0 μg/kg.
3. The method of claim 1 wherein the route of administration of the compound that is a selective partial A 2A adenosine receptor agonist is bolus.
4. The method of claim 1 wherein the selective partial A 2A adenosine receptor agonist compound is formulated into a liquid.
5. The method of claim 1 wherein the compound that is a selective partial A 2A adenosine receptor agonist is administered in a single dose.
6. The method of claim 1 wherein the compound that is a selective partial A 2A adenosine receptor agonist is CVT-3033.
7. The method of claim 6 wherein the route of administration of CVT-3033 is bolus.
8. The method of claim 6 wherein the CVT-3033 is formulated into a liquid.
9. The method of claim 6 wherein the CVT-3033 is administered in a single dose.
10. The method of claim 6 , wherein the dose of CVT-3033 is from 0.0002 to 0.009 mg/kg.
11. The method of claim 6 , wherein the dose of CVT-3033 is from 0.10 to 5.0 μg/kg.
12. A method for iincreasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A 2A adenosine receptor agonist to a mammal, wherein the selective partial A 2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.
13. The method of claim 12 , wherein the method of administration is bolus.
14. The method of claim 12 , wherein the dose of CVT-3033 is from 0.10 to 5.0 μg/kg.
15. A method of myocardial perfusion imaging of a mannnal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A 2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A 2A adenosine receptor agonist is CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl) and wherein the dose is from 0.0002 to 0.009 mg/kg.
16. The method of claim 15 , wherein the route of administration of CVT-3146 is bolus.
17. The method of claim 15 , wherein the CVT-3146 is formulated into a liquid.
18. The method of claim 15 , wherein the CVT-3146 is administered in a single dose.
19. The method of claim 15 , wherein the dose of CVT-3146 is from 0.10 to 5.0 μg/kg.
20. A method for increasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A 2A adenosine receptor agonist to the mammal, wherein the selective partial A 2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.
21. The method of claim 20 wherein the dose of CVT-3146 is from 0.10 to 5.0 μg/kg.
22. The method of claim 20 , wherein the method of administration is bolus.